Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Active, not recruiting · NCT05014646 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2026-04-30 | NCT05014646 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| City of Hope Medical Center | 347 |
| National Cancer Institute (NCI) | 3015 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atrium Health University City/LCI-University | Charlotte | United States | 1 |
| City of Hope Medical Center | Duarte | United States | 313 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Wayne State University/Karmanos Cancer Institute | Detroit | United States | 196 |